217 related articles for article (PubMed ID: 25595247)
1. Retinoic acid enhances the levels of IL-10 in TLR-stimulated B cells from patients with relapsing-remitting multiple sclerosis.
Eriksen AB; Berge T; Gustavsen MW; Leikfoss IS; Bos SD; Spurkland A; Harbo HF; Blomhoff HK
J Neuroimmunol; 2015 Jan; 278():11-8. PubMed ID: 25595247
[TBL] [Abstract][Full Text] [Related]
2. Retinoic acid improves defective TLR9/RP105-induced immune responses in common variable immunodeficiency-derived B cells.
Indrevær RL; Holm KL; Aukrust P; Osnes LT; Naderi EH; Fevang B; Blomhoff HK
J Immunol; 2013 Oct; 191(7):3624-33. PubMed ID: 24006462
[TBL] [Abstract][Full Text] [Related]
3. TLR9-signaling is required for turning retinoic acid into a potent stimulator of RP105 (CD180)-mediated proliferation and IgG synthesis in human memory B cells.
Eriksen AB; Indrevær RL; Holm KL; Landskron J; Blomhoff HK
Cell Immunol; 2012 Sep; 279(1):87-95. PubMed ID: 23103284
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid-induced IgG production in TLR-activated human primary B cells involves ULK1-mediated autophagy.
Eriksen AB; Torgersen ML; Holm KL; Abrahamsen G; Spurkland A; Moskaug JØ; Simonsen A; Blomhoff HK
Autophagy; 2015; 11(3):460-71. PubMed ID: 25749095
[TBL] [Abstract][Full Text] [Related]
5. B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis.
Ramgolam VS; Sha Y; Marcus KL; Choudhary N; Troiani L; Chopra M; Markovic-Plese S
J Immunol; 2011 Apr; 186(7):4518-26. PubMed ID: 21368231
[TBL] [Abstract][Full Text] [Related]
6. Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis.
Hirotani M; Niino M; Fukazawa T; Kikuchi S; Yabe I; Hamada S; Tajima Y; Sasaki H
J Neuroimmunol; 2010 Apr; 221(1-2):95-100. PubMed ID: 20227772
[TBL] [Abstract][Full Text] [Related]
7. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
Bar-Or A; Fawaz L; Fan B; Darlington PJ; Rieger A; Ghorayeb C; Calabresi PA; Waubant E; Hauser SL; Zhang J; Smith CH
Ann Neurol; 2010 Apr; 67(4):452-61. PubMed ID: 20437580
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS).
Tao Y; Zhang X; Markovic-Plese S
J Neuroimmunol; 2016 Sep; 298():181-8. PubMed ID: 27609294
[TBL] [Abstract][Full Text] [Related]
9. IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients.
Giacomini E; Severa M; Rizzo F; Mechelli R; Annibali V; Ristori G; Riccieri V; Salvetti M; Coccia EM
Eur J Immunol; 2013 Jul; 43(7):1963-72. PubMed ID: 23636665
[TBL] [Abstract][Full Text] [Related]
10. Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate.
Jung S; Siglienti I; Grauer O; Magnus T; Scarlato G; Toyka K
J Neuroimmunol; 2004 Mar; 148(1-2):63-73. PubMed ID: 14975587
[TBL] [Abstract][Full Text] [Related]
11. B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity.
Piancone F; Saresella M; Marventano I; La Rosa F; Zoppis M; Agostini S; Longhi R; Caputo D; Mendozzi L; Rovaris M; Clerici M
Sci Rep; 2016 Jul; 6():29699. PubMed ID: 27412504
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b.
Jensen MA; Yanowitch RN; Reder AT; White DM; Arnason BG
Mult Scler; 2010 Jan; 16(1):30-8. PubMed ID: 20007427
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
Hamamcioglu K; Reder AT
Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
[TBL] [Abstract][Full Text] [Related]
14. Signaling via toll-like receptor 4 and CD40 in B cells plays a regulatory role in the pathogenesis of multiple sclerosis through interleukin-10 production.
Okada Y; Ochi H; Fujii C; Hashi Y; Hamatani M; Ashida S; Kawamura K; Kusaka H; Matsumoto S; Nakagawa M; Mizuno T; Takahashi R; Kondo T
J Autoimmun; 2018 Mar; 88():103-113. PubMed ID: 29146546
[TBL] [Abstract][Full Text] [Related]
15. Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-α and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis.
Nielsen CH; Börnsen L; Sellebjerg F; Brimnes MK
PLoS One; 2016; 11(1):e0146971. PubMed ID: 26756931
[TBL] [Abstract][Full Text] [Related]
16. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
17. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
[TBL] [Abstract][Full Text] [Related]
18. Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.
Giacomini E; Rizzo F; Etna MP; Cruciani M; Mechelli R; Buscarinu MC; Pica F; D'Agostini C; Salvetti M; Coccia EM; Severa M
Mult Scler; 2018 Feb; 24(2):127-139. PubMed ID: 28273784
[TBL] [Abstract][Full Text] [Related]
19. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis.
Stasiolek M; Bayas A; Kruse N; Wieczarkowiecz A; Toyka KV; Gold R; Selmaj K
Brain; 2006 May; 129(Pt 5):1293-305. PubMed ID: 16513684
[TBL] [Abstract][Full Text] [Related]
20. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro.
Lisak RP; Benjamins JA; Nedelkoska L; Barger JL; Ragheb S; Fan B; Ouamara N; Johnson TA; Rajasekharan S; Bar-Or A
J Neuroimmunol; 2012 May; 246(1-2):85-95. PubMed ID: 22458983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
